CAS: 1513883-39-0; Ctp-543
- 英文名称Ctp-543
- 中文名称(R)-3-(4-(7H-B[2,3-D]嘧啶-4-基)-1H-H-1-基)-3-(环戊基-2,2,3,3,4,4,5,5-D8)丙腈
- IUPAC名称(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)propanenitrile
- CAS编号1513883-39-0
- FDA UNII编号:0CA0VSF91Y
- 分子式:C17H18N6分子量:306.37
- 产品CID: 738712
- 同类组份化合物CAS1513883-39-0 (free base)2147706-60-1 (phosphate)
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2926909090-其他腈基化合物
- 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2023322787-A1
优先权日:2020-08-12
标 题 :Process for preparing enantiomerically enriched jak inhibitors
发明人：WIEDEMANN SEAN; COWDEN CAMERON J; BAZINET PATRICK; KAVOURIS KATHRYN E; WU KUO-MING; LEWIS ROBERT S
权利人:CONCERT PHARMACEUTICALS INC
摘要:Certain aspects of the present invention are directed to improved processes for preparing enantiomerically enriched intermediates for the synthesis of ruxolitinib and deuterated forms of ruxolitinib. Certain aspects are also directed to deuterated intermediates useful in the synthesis of deuterated forms of ruxolitinib. Certain aspects are also directed to reaction mixtures for preparing enantiomerically enriched intermediates useful in the synthesis of ruxolitinib and deuterated forms of ruxolitinib.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, Prajapati VH, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman MC, Hamilton C, Cassella J. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024 Jul
23:S0190-9622(24)02550-7. doi: 10.1016/j.jaad.2024.06.097. Epub ahead of print. 33(5):441-449. doi: 10.1080/13543784.2024.2348062. Epub 2024 May 20.
15:1372810. doi: 10.3389/fphar.2024.1372810.
合成参考文献
参考文献:10.1111/imm.13175
摘要:Harding SD, Faccenda E, Southan C, Pawson AJ, Maffia P, Alexander SPH, Davenport AP, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA. The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology. Immunology. 2020 May;160(1):10–23.
参考文献:10.1080/17512433.2020.1702878
摘要:Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata – a promising new dawn Expert Review of Clinical Pharmacology. 2019 Dec 22;13(1):43–51. doi: 10.1080/17512433.2020.1702878.
📝 需求与反馈
尽可能描述清楚需求与问题信息
